ASGCT 23rd Annual Meeting
May 12-15, 2020
Thank You and Welcome to ASGCT's 23rd Annual Meeting
ASGCT is excited to host the field for the 23rd Annual Meeting, our first-ever virtual event.

Society leadership, staff, and member-volunteers are endlessly appreciative of the overwhelming response we've received to operating under unprecedented circumstances. Thank you all for your dedication to the field, and enjoy the meeting!
Thanks to our virtual sponsors
Agenda
    • 8:00 AM - 12:00 PM EST
      • CAR T-Cell and Immune Effectors Workshop
    • 8:00 AM - 12:00 PM EST
      • Clinical Trials Training I
    • 8:00 AM - 12:00 PM EST
      • Commercialization I Workshop
    • 8:00 AM - 12:00 PM EST
      • Stem Cell Therapies Workshop
    • 1:00 PM - 5:00 PM EST
      • Clinical Trials Training II
    • 1:00 PM - 5:00 PM EST
      • Gene Editing Workshop
    • 1:00 PM - 5:00 PM EST
      • Oncolytic Viruses Workshop
    • 1:00 PM - 5:00 PM EST
      • Viral Vector Development Workshop
    • 1:00 PM - 5:00 PM EST
      • Commercialization II Workshop
    • 8:00 AM - 9:45 AM EST
      • Advances in Therapeutic RNAi
        Organized by the Oligonucleotide and RNAi Therapeutics Committee
    • 8:00 AM - 9:45 AM EST
      • Developing New Therapies for Children with Metabolic Disorders
        Organized by the Gene & Cell Therapy of Genetic and Metabolic Diseases Committee
    • 8:00 AM - 9:45 AM EST
      • New Developments in Particles, Transfer Methods and Vectors for Gene Delivery
        Organized by the Physical Delivery, Therapeutics & Vector Development Committee
    • 8:00 AM - 9:45 AM
      • The Golden Age of Gene Therapy: Past, Present and Future Perspectives
    • 1:30 PM - 3:15 PM EST
      • “Off the Shelf” Cell Therapies
    • 1:30 PM - 3:15 PM EST
      • Adeno-associated Virus (AAV) Vectors - From Basic Biology to Vector Application
    • 1:30 PM - 3:15 PM EST
      • Bioinformatics: Artificial Intelligence (AI) takes Gene Therapy to the Next Level
    • 1:30 PM - 3:15 PM EST
      • Building Robust Animal Models for Preclinical Testing Gene and Immune Therapies for Humans
    • 1:30 PM - 3:15 PM EST
      • Engineered T cell Therapies for Malignancies
    • 1:30 PM - 3:15 PM EST
      • Gene Editing with CRISPR/Cas9, Discovery to Application
    • 8:00 AM - 9:45 AM EST
      • Ins and Outs of Lentiviral Vectors: From Technology to Applications
    • 1:30 PM - 3:15 PM EST
      • Synthetic Biology Meets Immunology: DNA and RNA Tools
    • 1:30 PM - 3:15 PM EST
      • Updates on Immunogenicity against AAV and Cas9
    • 10:15 AM - 12:00 PM EST
      • George Stamatoyannopoulos Memorial Lecture & Presentation of the Excellence in Research Awards
    • 1:30 PM - 3:15 PM EST
      • Outstanding New Investigator Symposium
    • 8:00 AM - 9:45 AM EST
      • Accessing Virus Vectors for Non-clinical and Clinical Gene Therapy Studies
        Organized by the Bio-Industry Committee
    • 8:00 AM - 9:45 AM EST
      • Advances in Allogeneic and Off-the-Shelf Hematopoietic Cell Therapies
        Organized by the Hematologic and Immunologic Gene and Cell Therapy Committee
    • 8:00 AM - 9:45 AM EST
      • Advancing Therapeutic Exosomes for the Treatment of Disease
        Organized by the Nanoagents & Synthetic Formulations Committee
    • 8:00 AM - 9:45 AM EST
      • Cell-based Therapies for Eye and Nervous System Disorders: Translation from Research to Early Clinical Stages
        Organized by the Neurologic & Ophthalmic Gene & Cell Therapy Committee
    • 8:00 AM - 9:45 AM EST
      • Challenges and Future Directions in Cardiovascular Gene and Cell Therapy
        Organized by the Cardiovascular Gene & Cell Therapy Committee
    • 8:00 AM - 9:45 AM EST
      • Challenges and Possible Solutions in Infectious Diseases
        Organized by the Infectious Diseases and Vaccines Committee
    • 8:00 AM - 9:45 AM EST
      • Clearing the Path to an IND: How we succeeded
        Organized by the Translational Science Committee
    • 8:00 AM - 9:45 AM EST
      • Engineering Immunity: CARs for non-B Cell Malignancies.
        Organized by the American Society for Transplantation and Cellular Therapy
    • 8:00 AM - 9:45 AM EST
      • Gene and Cell Therapeutic Strategies to Treat Disorders of the CNS – An International Perspective
        Organized by the International Committee
    • 8:00 AM - 9:45 AM EST
      • Gene Editing: Emerging New Technologies and Unbiased Assessment of On and Off Target Genome Alteration
        Organized by the Genome Editing Committee
    • 8:00 AM - 9:45 AM EST
      • Globalization Roadmap for Cell and Gene Therapies
        Organized by the Commercialization Committee
    • 8:00 AM - 9:45 AM EST
      • Latest Advances in Cancer Gene and Cellular Therapies
        Organized by the Cancer Gene & Cell Therapy Committee
    • 8:00 AM - 9:45 AM EST
      • Pharmacovigilance and Long Term Follow up of Gene Therapies in the Post-Approval World
        Organized by the Regulatory Affairs Committee
    • 8:00 AM - 9:45 AM EST
      • Social, Ethical, and Scientific Perspectives on Germline Gene Editing
        Organized by the Ethics and Government Relations Committees
    • 8:00 AM - 9:45 AM EST
      • Stem Cell-derived Organoids
        Organized by the Stem Cell Committee
    • 8:00 AM - 9:45 AM EST
      • Successes in Gene Therapy for Musculoskeletal Disease
        Organized by the Musculo-Skeletal Gene & Cell Therapy Committee
    • 8:00 AM - 9:45 AM EST
      • Targeting the Lung: Vectors and Stem Cells
        Organized by the Respiratory & GI Tract Gene & Cell Therapy Committee
    • 8:00 AM - 9:45 AM EST
      • Vector Development, Clinical Implementation, and Corporate Connections
        Organized by the Viral Gene Transfer Vectors Committee
    • 10:15 AM - 12 PM EST
      • CAR T-Cell Therapies I
    • 10:15 AM - 12 PM EST
      • Cancer - Targeted Gene and Cell Therapy
    • 3:45 PM - 5:30 PM EST
      • CAR T-Cell Therapies II
    • 10:15 AM - 12 PM EST
      • CAR T-Cells Targeting Solid Tumors
    • 10:15 AM - 12 PM EST
      • Assay Development
    • 10:15 AM - 12 PM EST
      • Genome Editing: Preclinical & Rare Disease
    • 3:45 PM - 5:30 PM EST
      • AAV Vectors Preclinical and Proof-of-Concept Studies in Optimizing the Toolbox
    • 3:45 PM - 5:30 PM EST
      • Musculo-skeletal Diseases I
    • 3:45 PM - 5:30 PM EST
      • Oligonucleotide Therapies for Acquired Diseases
    • 3:45 PM - 5:30 PM EST
      • Hematopoietic Cell Therapies
    • 10:15 AM - 12 PM EST
      • Gene Therapy for the Special Senses
    • 10:15 AM - 12 PM EST
      • Vector and Cell Engineering, Production or Manufacturing I
    • 3:45 PM - 5:30 PM EST
      • Evaluating Genome Editing Activity and Precision
    • 3:45 PM - 5:30 PM EST
      • HSPC Gene Therapies for Blood and Immune Disorders
    • 10:15 AM - 12 PM EST
      • Oligonucleotide Therapies for Genetic Diseases
    • 3:45 PM - 5:30 PM EST
      • Vector and Cell Engineering, Production or Manufacturing II
    • 3:45 PM - 5:30 PM EST
      • CAR T and Other Engineered T Cells Targeting Hematological Malignancies
    • 3:45 PM - 5:30 PM EST
      • AAV Vectors - Clinical Studies II
    • 3:45 PM - 5:30 PM EST
      • HSPC Gene Therapies for Blood and Immune Disorders
    • 12:00 PM - 1:30 PM EST
      • Transitioning from Academics to Industry
    • 3:45 PM - 5:30 PM EST
      • Clinical Gene Therapies for Inborn Errors of Metabolism
    • 3:45 PM - 5:30 PM EST
      • Applications of Physical, Chemical and Exosomal Delivery
    • 8:00 AM - 9:45 AM EST
      • Career Development in Academia and Industry
    • 12:00 PM - 1:30 PM EST
      • Molecular Therapy Lunch Session
    • 3:45 PM - 5:30 PM EST
      • Vector and Cell Engineering, Production or Manufacturing III
    • 8:00 AM - 9:45 AM EST
      • Strategies for Preparing Synthetic Vectors for Clinical Application
    • 3:45 PM - 5:30 PM EST
      • HSPC Gene Therapies for Hemoglobin Disorders
    • 10:15 AM - 12:00 PM EST
      • Outstanding Achievement Award Lecture & Presentation & Sonia Skarlatos Public Service Award
    • 1:15 PM - 3:45 PM EST
      • Presidential Symposium & Presentation of the Top Abstracts
    • 3:45 PM - 5:30 PM EST
      • Viral Vector Development: RNA Virus Vectors
    • 12:00 PM - 1:30 PM EST
      • Industry Sponsored Symposium: Terumo BCT
    • 12:00 PM - 1:30 PM EST
      • Industry Sponsored Symposium: FUJIFILM Diosynth Biotechnologies
    • 3:45 PM - 5:30 PM EST
      • Musculo-skeletal Diseases II
    • 12:00 PM - 1:30 PM EST
      • Industry Sponsored Symposium: PTC Therapeutics
    • 3:45 PM - 5:30 PM EST
      • New Techniques in Gene Therapy for Neurological Disorders
    • 12:00 PM - 1:30 PM EST
      • Tools and Technologies Forum 5
    • 3:30 PM - 5:30 PM EST
      • Tools and Technologies Forum 6
    • 3:45 PM - 5:30 PM EST
      • Gene Therapies for Hemophilia and Immune Disorders
    • 12:00 PM - 1:30 PM EST
      • Industry Sponsored Symposium: GenScript USA Inc.
    • 3:45 PM - 5:30 PM EST
      • AAV Vectors Preclinical and Proof-of-Concept Studies in Systemic Diseases
    • 12:00 PM - 1:30 PM EST
      • Navigating Career Paths for Trainees
    • 3:45 PM - 5:30 PM EST
      • Tolerance and Vaccine Approaches
    • 12:00 PM - 1:30 PM EST
      • Characterizing and Minimizing Genome Editing Off-Target Effects
    • 3:45 PM - 5:30 PM EST
      • Genome Editing in Inborn Errors of Metabolism
    • 8:00 AM - 9:45 AM EST
      • IND-Enabling NIH Resources to Advance Clinical and Translational Gene Therapy
    • 3:45 PM - 5:30 PM EST
      • Vector and Cell Engineering, Production or Manufacturing IV
    • 3:45 PM - 5:30 PM EST
      • Pharmacology/Toxicology Studies
    • 8:00 AM - 9:45 AM EST
      • The Long-term View: Extended follow up of Patients in Pivotal Gene Therapy Trials
    • 10:15 AM - 12:00 PM EST
      • AAV Vectors - Clinical Studies I
    • 10:15 AM - 12:00 PM EST
      • AAV Vectors Preclinical and Proof-of-Concept Studies in CNS Disorders
    • 10:15 AM - 12:00 PM EST
      • Gene Regulation and Delivery Technologies
    • 10:15 AM - 12:00 PM EST
      • Physical, Chemical and Exosomal Gene Delivery
    • 7:30 AM - 8:00 AM EST
      • Business Meeting
    • 8:00 AM - 9:45 AM EST
      • Growing Gene and Cell Therapy (GGACT):
        An NCATS-funded collaborative effort to support development of academic clinical trials for rare diseases
    • 10:15 AM - 12:00 PM EST
      • Cardiovascular and Pulmonary Diseases
    • 10:15 AM - 12:00 PM EST
      • Cancer Immunotherapy: Clinical Results
    • 8:00 AM - 9:45 AM EST
      • 2019 Career Development Award Recipients
    • 10:15 AM - 12:00 PM EST
      • Gene Therapy for Inborn Errors of Metabolism: New Approaches
    • 8:00 AM - 9:45 AM EST
      • Clinical Trials Spotlight Symposium
    • 10:15 AM - 12:00 PM EST
      • Technical Advances in Cell Therapies
    • 10:15 AM - 12:00 PM EST
      • Vector and Cell Engineering, Production or Manufacturing V
    • 10:15 AM - 2:00 PM EST
      • Cancer - Oncolytic Viruses
    • 3:45 PM - 5:30 PM EST
      • New Gene Editing Technologies and Approaches
    • 3:45 PM - 5:30 PM EST
      • AAV Vector Biology: New Insights
    • 10:15 AM - 12:00 PM EST
      • Advances in AAV Vector Engineering
    • 3:45 PM - 5:30 PM EST
      • AAV Gene Delivery for CNS Disorders
    • 12:00 PM - 1:30 PM EST
      • Tools and Technologies Forum 1
    • 3:30 PM - 5:30 PM EST
      • Tools and Technologies Forum 2
    • 10:15 AM - 12:00 PM EST
      • Immune Responses Against AAV Vectors
    • 3:45 PM - 5:30 PM EST
      • Antiviral Immunotherapy
    • 12:00 PM - 1:30 PM EST
      • Industry Sponsored Symposium: Cytvia
    • 3:45 PM - 5:30 PM EST
      • Preclinical Large Animal Studies for Neurologic Diseases
    • 12:00 PM - 1:30 PM EST
      • Industry Sponsored Symposium: Sarepta Therapeutics
    • 12:00 PM - 1:30 PM EST
      • Industry Sponsored Symposium: Pall Biotech
    • 3:45 PM - 5:30 PM EST
      • AAV Vectors – Clinical Studies II
    • 12:00 PM - 1:30 PM EST
      • Tools and Technologies Forum 3
    • 3:30 PM - 5:30 PM EST
      • Tools and Technologies Forum 4
    • 3:45 PM - 5:30 PM EST
      • Controlling AAV Gene Expression: Shifting Paradigms
    • 3:45 PM - 5:30 PM EST
      • AAV Vector Development: Towards Translation
Attend the Premier Event in Gene & Cell Therapy